MTOR and autosomal dominant polycystic kidney disease: mTOR signalling is up‐regulated in a wide variety of cancers and is regarded as one of the most frequently altered cascades in this heterogeneous disease.29, 30, 31 mTOR signalling is increased in mouse models of PKD and human ADPKD, while mTOR inhibitors, such as sirolimus and everolimus, slow disease progression in PKD animal models.12, 32, 33, 34 The Jak/STAT pathway is also deregulated in both cancer and PKD.